Mitochondria possess their own mRNA translation system, mediated by specialized mitoribosomes. Dysregulation of mitochondrial translation disrupts metabolic homeostasis and is linked to various ...

MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

This webcast features: Andrew Worden, Chief Technology Officer, Vector BioMed. Scaling up production of lentivirus vectors (LVVs) is a complicated process. It usually begins with flask-based cultures ...

ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, celebrated the opening of its facility in Hopewell, New Jersey. The facility will ...

HOPEWELL, N.J., June 27, 2025 /PRNewswire/ -- ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.

According to the latest report Europe viral vector and plasmid DNA manufacturing market size is estimated to be worth USD 2.22 billion in 2024 and is anticipated to reach a value of USD 11.65 billion ...

Differences between the lentiviral vectors used in these studies could have led to the varied results; for example, in contrast to Lenti-D, BB305 lentiviral vector leads to lineage-restricted ...